The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 28, 2020
Filed:
Jul. 27, 2018
Applicants:
Celator Pharmaceuticals, Inc., Ewing, NJ (US);
Lawrence Mayer, North Vancouver, CA;
Inventors:
Paul Tardi, Surrey, CA;
Troy Harasym, North Vancouver, CA;
Murray Webb, North Vancouver, CA;
Clifford Shew, Vancouver, CA;
Andrew Janoff, Yardley, PA (US);
Lawrence Mayer, North Vancouver, CA;
Marcel Bally, Bowen Island, CA;
Assignee:
Celator Pharmaceuticals, Inc., Ewing, NJ (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/127 (2006.01); A61K 31/00 (2006.01); A61K 31/337 (2006.01); A61K 31/4745 (2006.01); A61K 31/704 (2006.01); A61K 31/7048 (2006.01); A61K 31/7072 (2006.01); A61K 31/7076 (2006.01); A61K 33/24 (2019.01); A61K 45/06 (2006.01); A61K 31/133 (2006.01); A61K 31/17 (2006.01); A61K 31/475 (2006.01); A61K 31/513 (2006.01); A61K 31/519 (2006.01); A61K 31/555 (2006.01); A61K 31/575 (2006.01); A61K 31/685 (2006.01); A61K 31/7068 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 9/127 (2013.01); A61K 9/1271 (2013.01); A61K 9/1272 (2013.01); A61K 31/00 (2013.01); A61K 31/133 (2013.01); A61K 31/17 (2013.01); A61K 31/337 (2013.01); A61K 31/475 (2013.01); A61K 31/4745 (2013.01); A61K 31/513 (2013.01); A61K 31/519 (2013.01); A61K 31/555 (2013.01); A61K 31/575 (2013.01); A61K 31/685 (2013.01); A61K 31/704 (2013.01); A61K 31/7048 (2013.01); A61K 31/7068 (2013.01); A61K 31/7072 (2013.01); A61K 31/7076 (2013.01); A61K 33/24 (2013.01); A61K 39/00 (2013.01); A61K 45/06 (2013.01);
Abstract
Compositions which comprise delivery vehicles having stably associated therewith non-antagonistic combinations of two or more agents, such as antineoplastic agents, are useful in achieving non-antagonistic effects when combinations of drugs are administered.